Ref: Syn/CS/SE/PR/July 2018 - 012

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099, India
T +91 80 6775 8000
F +91 80 6775 8808
CIN: L85110KA1993PLC014937

www.syngeneintl.com

July 23, 2018

To,	To,
The Manager Listing	The Manager Listing
BSE Limited	National Stock Exchange of India Limited
Corporate Relationship Department	Corporate Communication Department
Dalal Street, Mumbai – 400 001	Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	**Scrip Symbol: SYNGENE**

Dear Sir/Madam,

Subject: Press Release

This has reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Please find enclosed the press release titled **"Syngene International Expands Collaboration with Baxter".**

The above mentioned press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

MAYANK VERMA Digitally signed by MAYANK VERMA Date: 2018.07.23 15:34:07 +05'30'

Mayank Verma
Company Secretary



PRESS RELEASE

Syngene International Expands Collaboration with Baxter

23 July, 2018; Bengaluru, India

Syngene International Ltd., a leading global Contract Research Organization, announced the expansion of the scope of its R&D collaboration with Baxter Healthcare Corporation, a global healthcare company. As part of the expansion, Syngene will set up additional infrastructure at the dedicated Baxter Global Research Center (BGRC) as well as increase the size of its scientific team working on Baxter projects. The duration of the agreement has also been extended until 2024.

Syngene and Baxter originally established the Baxter Global Research Center, a dedicated R&D center, in 2013.

Mr. Jonathan Hunt, Chief Executive Officer, Syngene International Limited, said, *"We are very proud of our work with Baxter and the expansion of our collaboration. We advance excellent science at Syngene and our dedicated R&D Center business model allows us to offer integrated scientific solutions to clients."*

Syngene presently operates dedicated R&D Centers for Bristol-Myers Squibb, Amgen and Herbalife, in addition to Baxter.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), a global discovery, development and manufacturing organization for novel molecules, provides integrated services to pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemicals industries across the world. Syngene's clientele include market leaders like Bristol-Myers Squib, Baxter, Amgen, GSK, Zoetis, Merck KGaA and Herbalife. Its innovative culture is driven by a strong team of over 3500



PRESS RELEASE

scientists working with clients to improve R&D productivity, while reducing the development time and cost. For more details, visit www.syngeneintl.com.

For further information, please reach out to:

Investor Contact	**Media Contact**
Chanderlekha Nayar P: +91 80 6775 8821 M: +91 72591 92001 Fax: +91 80 2852 3423 E: chanderlekha.nayar@syngeneintl.com	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com